“The Russian study concerns 76 patients. The Russian Minister of Health himself stated that it will be used only for internal purposes”. With these words Silvio Garattini, president of the Mario Negri Institute commented on the latest news from Russia on the vaccine experimentation against Covid-19.

Garattini doubts that a vaccine at this stage of the trial can be approved by European regulators. For that of Oxford, the president shows cautious optimism: “It is very likely that we will soon have some data to think about”.

Foto Lapresse/Matteo Corner

There are “seven most advanced and promising anti-Covid vaccine candidates in the world, in addition to Sputnik V which is a little behind. Only few data have been published on this product and on a small number of patients: if there are any side effects, may not have emerged. ” To make the point with Adnkronos Salute is Silvio Garattini, president of the Mario Negri Institute of Pharmacological Research in Milan. Approximately 33% of vaccine candidates pass phase III and hit the market, “and at this point we can hope that more than one of the 7 most advanced candidates will make it to the end of the trial by the end of the year. As they have already started producing millions of doses, if the studies go well these will soon be available. Otherwise – says the pharmacologist – they will throw everything away.

According to the pharmacologist, the Chinese vaccine from CanSino, the first candidate to reach phase 1 and phase 2, is part of the group of the most advanced and promising candidates, together with products developed by Sinovac, Sinopharm, AstraZeneca (in collaboration with Oxford and the Italian Irbm of Pomezia), by the US candidate Modern / Niaid, the BionTech / Pfizer candidate and the Australian candidate from the University of Melbourne / Murdoch Children’s Research Institute. The Russian Sputnik V joins this squad. Italy is also part of the vaccine race, with the Reithera serum experimentation started at Spallanzani, and the Takis / Rottapharm product.

The announcements on the Russian vaccine have caused a sensation in recent weeks, the first data of which were recently published in the Lancet. “But this is still initial evidence – underlines Garattini – which may not highlight the side effects that may occur in one case out of a thousand. Furthermore, according to what has been said, this vaccine will only be available for Russia”, he concludes.